Patent ID: 11885806
Assignee: AUTOLUS LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC A  C  G

Claim 2:
3. A method of selectively depleting TRBC1 positive malignant T-cells without depleting the entire T-cell compartment in a human subject, the method comprising:
determining whether a malignant T cell in a sample containing T cells from the subject expresses TRBC1, and
selectively depleting malignant and normal T-cells in the subject that express TRBC1 by administering to the subject an agent that selectively binds to TRBC1 and that depletes said malignant and normal T-cells,, wherein the agent is an engineered T-cell expressing a CAR that selectively binds to TRBC1 and that comprises (a) an antigen-binding domain comprising a variable heavy chain (VH) comprising: a VH CDR1 of SEQ ID NO: 7, a VH CDR2 of SEQ ID NO: 8, and a VH CDR3 of SEQ ID NO: 9, and a variable light chain (VL) comprising a VL CDR1 of SEQ ID NO: 10, a VL CDR2 of SEQ ID NO: 11, and a VL CDR3 of SEQ ID NO: 12, and (b) comprises a spacer comprising an IgG1 hinge or a CD8 stalk.